Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease
ML Agostini, EL Andres, AC Sims, RL Graham… - MBio, 2018 - Am Soc Microbiol
Emerging coronaviruses (CoVs) cause severe disease in humans, but no approved therapeutics
are available. The CoV nsp14 exoribonuclease (ExoN) has complicated development …
are available. The CoV nsp14 exoribonuclease (ExoN) has complicated development …
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
…, RL Graham, AJ Pruijssers, ML Agostini… - Science translational …, 2020 - science.org
Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks,
most recently exemplified by the newly emerged SARS-CoV-2, the causative agent of …
most recently exemplified by the newly emerged SARS-CoV-2, the causative agent of …
[PDF][PDF] Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice
…, LE Gralinksi, KH Dinnon, BL Yount, ML Agostini… - Cell reports, 2020 - cell.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
the novel viral disease COVID-19. With no approved therapies, this pandemic illustrates the …
the novel viral disease COVID-19. With no approved therapies, this pandemic illustrates the …
The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
…, FA Lempp, D Ma, MA Schmid, ML Agostini… - biorxiv, 2021 - biorxiv.org
VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs) targeting the spike
glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-7831 …
glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-7831 …
[HTML][HTML] The coronavirus proofreading exoribonuclease mediates extensive viral recombination
J Gribble, LJ Stevens, ML Agostini… - PLoS …, 2021 - journals.plos.org
Recombination is proposed to be critical for coronavirus (CoV) diversity and emergence of
SARS-CoV-2 and other zoonotic CoVs. While RNA recombination is required during normal …
SARS-CoV-2 and other zoonotic CoVs. While RNA recombination is required during normal …
Small-Molecule Antiviral β-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
ML Agostini, AJ Pruijssers, JD Chappell… - Journal of …, 2019 - Am Soc Microbiol
Coronaviruses (CoVs) have emerged from animal reservoirs to cause severe and lethal
disease in humans, but there are currently no FDA-approved antivirals to treat the infections. …
disease in humans, but there are currently no FDA-approved antivirals to treat the infections. …
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus
…, A Schäfer, KH Dinnon III, SA Montgomery, ML Agostini… - Biorxiv, 2020 - biorxiv.org
Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks,
most recently exemplified by the newly emerged SARS-CoV-2. Herein, we show that the …
most recently exemplified by the newly emerged SARS-CoV-2. Herein, we show that the …
A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance
…, J Gribble, AJ Pruijssers, ML Agostini… - Mbio, 2023 - Am Soc Microbiol
Coronaviruses (CoVs) encode nonstructural proteins 1–16 (nsps 1–16) which form
replicase complexes that mediate viral RNA synthesis. Remdesivir (RDV) is an adenosine …
replicase complexes that mediate viral RNA synthesis. Remdesivir (RDV) is an adenosine …
Intramuscular vs intravenous SARS-CoV-2 neutralizing antibody sotrovimab for treatment of COVID-19 (COMET-TAIL): a randomized noninferiority clinical trial
…, D Austin, A Peppercorn, ML Agostini… - Open forum …, 2023 - academic.oup.com
Background Convenient administration of coronavirus disease 2019 (COVID-19) treatment
in community settings is desirable. Sotrovimab is a pan-sarbecovirus dual-action monoclonal …
in community settings is desirable. Sotrovimab is a pan-sarbecovirus dual-action monoclonal …
Fitness barriers limit reversion of a proofreading-deficient coronavirus
KW Graepel, ML Agostini, X Lu, NR Sexton… - Journal of …, 2019 - Am Soc Microbiol
The 3′-to-5′ exoribonuclease in coronavirus (CoV) nonstructural protein 14 (nsp14-ExoN)
mediates RNA proofreading during genome replication. ExoN catalytic residues are …
mediates RNA proofreading during genome replication. ExoN catalytic residues are …